Opens in a new tab

A Second Step for Alzheimer’s Blood Tests

A European study found that an added laboratory step helped distinguish Alzheimer-related brain-derived tau from a potentially confounding signal in people with ALS. The method could clarify selected discordant blood-test results after further validation.

November 6, 2026
Editorial
The source of a blood biomarker matters when another condition can affect its interpretation.Svitlana Hulko / Shutterstock.com

IPM Take

As Alzheimer’s blood tests move closer to care pathways, an inaccurate interpretation can have practical consequences. This study shows why a raised p-tau217 result may need a second look in someone with ALS or another condition that could release peripheral tau. A selective confirmation strategy is more plausible than adding a complex step to every test.

Executive Summary

The study analysed serum from 139 people with ALS, 101 with Alzheimer’s disease and 75 disease controls. Direct assays found elevated tau measures in both disease groups. After an immunoprecipitation step designed to enrich brain-derived tau, the elevation remained in Alzheimer’s disease but not ALS. In a subset comparison, discrimination between Alzheimer’s and ALS improved from an area under the curve of 0.729 with direct p-tau217 testing to 0.900 after the additional step. The method requires standardisation and independent validation before routine use.

Why it matters

  • Patients: Clarifying a discordant result could reduce unnecessary worry and inappropriate onward decisions.
  • Clinicians: A biomarker must be interpreted with the patient’s symptoms and other neurological conditions.
  • Diagnostics / pathology: Laboratories may eventually need a defined second-line process for results vulnerable to peripheral tau interference.
  • Payers and industry: Additional testing should show that its greater specificity changes decisions enough to justify complexity and cost.

The tau-isoform study in Nature Communications asks a question that matters when blood biomarkers leave specialist research settings: does a raised value always reflect the intended brain pathology? Researchers found that direct serum measures were elevated in both Alzheimer’s disease and ALS. Tissue analysis indicated that larger tau forms outside the central nervous system, including in muscle, could confound interpretation.

The investigators then added an immunoprecipitation step to enrich brain-derived tau before measurement. In their cohort, the resulting pattern distinguished Alzheimer’s disease from ALS more clearly. That is particularly relevant when the first result is borderline, clinically unexpected or obtained from someone with a neuromuscular condition.

The accuracy estimate comes from a study comparison, not from a prospective test of routine clinical decisions. The extra laboratory step also requires equipment, standardisation and time. A future pathway might use a straightforward first test for most patients and reserve a more specific method for selected discordant cases, but that proposal needs independent validation and evaluation of its effect on patient care.

Source & Evidence